Get the Stockscreener App
78.00
2.01%
1.54
After Hours:
78.26
0.26
+0.33%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $78.00, with a volume of 21.30M.
It is up +2.01% in the last 24 hours and down -17.71% over the past month.
See More
Previous Close:
$76.46
Open:
$76.89
24h Volume:
21.30M
Relative Volume:
1.32
Market Cap:
$199.22B
Revenue:
$64.17B
Net Income/Loss:
$17.12B
P/E Ratio:
11.59
EPS:
6.73
Net Cash Flow:
$18.10B
1W Performance:
+0.58%
1M Performance:
-17.71%
6M Performance:
-28.93%
1Y Performance:
-37.78%
1-Day Range:
$76.88
$78.75
1-Week Range:
$75.93
$80.02
52-Week Range:
$75.93
$134.63
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
78.00 | 199.22B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Why Merck, Black Hills, And Virtus Investment Partners Are Winners For Passive Income - Benzinga
Is Merck & Co., Inc. (MRK) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Assessing Merck & Co: Insights From 9 Financial Analysts - Benzinga
Is Merck & Co., Inc. (MRK) The Dirt Cheap Stock To Invest In Now? - Yahoo Finance
BMO Capital Adjusts Merck Price Target to $89 From $96 - marketscreener.com
Leerink Partners Adjusts Price Target on Merck to $115 From $113, Keeps Outperform Rating - MarketScreener
Merck & Co., Inc. (MRK): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock - Yahoo Finance
Companion Animal Medicine Market Top PlayersMerck & Co., Inc.; - openPR.com
Empyema Market Deep Research Report with Forecast by 2032 | Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc - openPR.com
Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Is Merck & Co Inc. (NYSE:MRK) the Most Undervalued Quality Stock to Buy Now? - Insider Monkey
Rep. Kelly Morrison Sells Off Shares of Merck & Co., Inc. (NYSE:MRK) - Defense World
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Price Over Earnings Overview: Merck & Co - Benzinga
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery - Benzinga
April 14, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRK - TradingView
Merck & Co. Inc. (MRK): Among the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Rep. Marjorie Taylor Greene Buys Merck & Co., Inc. (NYSE:MRK) Stock - Defense World
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
Merck to Integrate Medical Resources Into Microsoft's Health Care AI Platform - MarketScreener
Is Merck & Co. (NYSE:MRK) a Cheap NYSE Stock to Invest in According to Hedge Funds? - Insider Monkey
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Business Wire
What to Expect From Merck & Co.'s Next Quarterly Earnings Report - TradingView
What To Expect From Merck & Co.'s Next Quarterly Earnings Report - Barchart.com
Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MRK Investors Have Final Opportunity Today to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Is Merck & Co., Inc. (MRK) the Best Medical Stock to Buy According to Billionaires? - Insider Monkey
MRK Deadline Tomorrow: MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - PR Newswire
FINAL MRK DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Merck & Co., Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Merck & Co., Inc. (NYSE:MRK) Stock Price Down 2.6%Here's What Happened - MarketBeat
MRK DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. - Bluefield Daily Telegraph
MRK DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK - GlobeNewswire Inc.
Merck & Co., Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion - TradingView
Jim Cramer on Merck (MRK): Stay The Course… It’s Been a Real Tough One - Yahoo Finance
MRK STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
MRK Lawsuit Alert! Class Action Lawsuit Against Merck & Company - TipRanks
Investors who lost money on Merck & Co., Inc.(MRK) should contact Levi & Korsinsky about pending Class ActionMRK - PR Newswire
Merck (MRK) Faces Shareholder Proposals Amid Market Challenges - GuruFocus
Merck (MRK) Poised for Growth with Strong Financial Performance - GuruFocus
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion - TradingView
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors – Contact ... - Eagle-Tribune
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - PR Newswire
Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey
Investor Sues Merck Executives, Board Over Misleading Comments - Bloomberg Law News
Merck & Co Inc Says CEO Robert M. Davis's 2024 Total Compensation Was $23.2 MillionSEC Filing - MarketScreener
MRK FINAL DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK - TradingView
Investors who lost money on Merck & Co., Inc. (MRK) should contact The Gross Law Firm about - Bluefield Daily Telegraph
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
1.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):